Useful links
Thyroid Cancer Research Group
Expanding translational research in thyroid cancer therapeutics
Our research group is comprised of surgeons, physicians, scientists, pathologists, clinical trial nurses, patient representative who meet to prioritise and develop research in the diagnosis and management of thyroid cancer.
Our researchers have demonstrated high impact publications and are recipients of NHMRC, Cancer Institute, Lincoln Centre, Cancer Council, University of Sydney Research Fund, Ramsay Health, Rebecca Cooper Foundation, Avant Foundation, Phaeo/Para Alliance and HCF Research Foundation grants.
Our senior researchers have outstanding H-indexes and demonstrate a >200+ publication list.
Research themes
Our aim is to establish a comprehensive personalised approach to thyroid cancer management across the full spectrum of the disease, utilising evidence-based algorithms.
Our overarching goal aims to prevent the unnecessary overtreatment of low risk thyroid cancer (minimising unnecessary harm) and to develop a personalised genomic and clinicopathologic profile of advanced thyroid cancer to expedite effective targeted therapy and improve patient outcomes.
Our group has expertise in translational research as well as clinical experience in endocrine cancer. We already have a strategic pipeline of research across the spectrum of thyroid cancer with many projects involving junior scientists and clinicians.
Research goals
- Accelerate translation of research outcomes in diagnostics of thyroid cancer.
- Improve patient knowledge and experience.
- Foster collaboration with to ensure individualised treatment for patients is achieved.
- Cultivate pipeline of emerging researchers and experts.
Our current research projects include analysis of ctDNA, tailoring radioactive iodine therapy, risk stratification of thyroid nodules, machine learning models, pathological grading of endocrine cancers, utility of DOTATE-PET scans in thyroid cancer diagnosis.
With your help, our translational research can be accelerated and improve the quality of life and survival outcomes for patients with thyroid cancer.
If you are considering making a major gift or leaving a gift in will for our research, please contact one of our development professionals who will be able to discuss how you can give and the impact your gift could have.
Our people
- Associate Professor Matti Gild (Chair)
- Professor Roderick Clifton-Bligh
- Assistant Professor Anthony Glover
- Assistant Professor Venessa Tsang
- Professor Bruce Robinson
- Professor Anthony Gill
- Dr Martyn Bullock
- Ms Rhonda Siddall
- Ms Yue Zhao
- Associate Professor Angela Chou
- Dr Ayanthi Wijewardene
- Dr John Turchini
- Dr Lyndal Tacon
- Dr Mahsa Ahadi
- Professor Mark Sywak
- Professor Stan Sidhu
- Associate Professor Tom Eade
- Ms Pip Coomes
We collaborate with many other colleagues across NSW including paediatrics, implementation science and oncology. Contact us to find out more.
- Dr Eleanor White
- Dr Jessica Bindra
- Dr Sumathy Perampalam
- Dr Linh Nguyen
If you're a PhD, Honours or Masters student and are interested in our work, contact our Research Chair, Dr Matti Gild for how you can get involved.
- Discovery of molecular therapeutic targets in PDTC
- Liquid biopsy optimisation techniques and clinical applications in thyroid cancer
- Royal Australasian College of Surgeons (RACS) John Mitchell Crouch Fellowship: "Improving outcomes for patients with advanced thyroid cancer"
- Ramsay Research Trust Fund
- Ramsay Research Trust Fund: "Clinical utility of serum thyroglobulin analysis by mass spectrometry in thyroid cancer"
- Royal College of Pathologists Australia (RCPA) Grant-in-Aid: "Clinical utility of serum thyroglobulin analysis by mass spectrometry in thyroid cancer"
- Endocrine Society of Australia (ESA) Research Seed Grant
Top research publications
- Zeng PYF… Clifton-Bligh R…, Delbridge L, Sidhu S, Sywak M, Robinson B… , Gill AJ, Clayman G, Boutros PC, Nichols AC. “The genomic and evolutionary landscapes of anaplastic thyroid carcinoma”. Cell Rep. 2024 Mar 26;43(3):113826.
- Wijewardene, A….Gild ML “Evaluating the Prognostic Potential of Circulating Cell-Free DNA in Advanced Thyroid Cancer. Endocrine Related Cancer in press
- Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 Sep 20;42(27):3187-3195.
- Wijewardene A, Gild M, … Clifton-Bligh R. Reducing noise in radioactive iodine activity selection: the utility of an online clinical calculator. Endocr Connect. 2024 Oct ;13(11):e240299.
- Lawless AK, Kumar S, Bindra J, Sywak M, Chou A, Turchini J, Papachristos A, Wijewardene A, Sidhu S, Ahadi M, Tacon L, Glover A, Clark K, Tsang V, Pang L, Clifton-Bligh RJ, Robinson B, Gill AJ, Guminski A, Eade T, Gild ML. Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol. Asia Pac J Clin Oncol. 2024 Aug 15.
- Perampalam S, Wu K, Gild ML, Tacon L, Bullock M, Clifton-Bligh R. Association between lymphocytic thyroiditis and papillary thyroid cancer harboring mutant BRAF: a systematic review and meta-analysis. Thyroid. 2024 Jun 28.
- Matrone, A., Kroiss M., Gild, ML ….Robinson BG., Elisei, R. “Erectile dysfunction in patients treated with selpercatinib for RET altered thyroid cancer” Thyroid in press
- Wu K, Kumar S, Hsiao E, Kerridge I, Qiu MR, Siddall R, Clifton-Bligh R, Gill AJ, Gild ML. Pulmonary BRAF-driven Langerhans cell histiocytosis following selpercatinib use in metastatic medullary thyroid cancer. Endocrinol Diabetes Metab Case Rep. 2024 May 27;2024(2):23-0079.
- McNeil, J, Gild, M., Tsang V., “Determining an Approach to Discharge from Oncologic Follow-up in Low-Risk, Well-Differentiated Thyroid Cancer with Excellent Response To Initial Therapy” Clinical Thyroidology 7 May 2024
- Gild ML*, Russel M*….Randolph G "Neoadjuvant Therapy to Improve Resectability of Advanced Thyroid Cancer: a Real-World Experience" Head and Neck in press
- Gild ML…Hoang J “The Clinical Utility of 68Ga-DOTATATE PET scanning in Medullary Thyroid Cancer” Endocrine Practice 2024 Mar;30(3):218-224.
- Gild ML, Wong, J, Staples, N, Schnitzler, M “Response to Zadow et al “Dietitians' perspective: Fostering momentum for planetary health change” Focus on Health Professional Education, in press
- Aksoy YA … Gild ML…Fuchs TL. Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma Histopathology. 2024 Jan 22.
- Kumar, S., Gild ML, Tsang V.“ Reexamining the Utility of Measuring Thyroperoxidase and Thyroglobulin Antibodies in Medically Treated Graves’ Disease and Orbitopathy“ Clinical Thyroidology March 2024
- White, E., Gild ML, Tsang, V “Patients Electing Active Surveillance for Low-Risk Papillary Thyroid Cancer Have Lower Baseline Anxiety”, Clinical Thyroidology July 2023, https://doi.org/10.1089/ct.2023;35.290-292
- Bindra, J., Gild ML, Tsang V.” Preoperative Molecular Profiling of Bethesda V and Bethesda VI Thyroid Nodules May Inform Initial Surgical Approach and the Intensity of Postoperative Surveillance” Clinical Thyroidology, Sept 23 https://doi.org/10.1089/ct.2023;35.371-374
- Wijewardene, A., Gild ML, Tsang V. Prognostic Indexes for Anaplastic Thyroid Cancer, Clinical Thyroidology, Dec 23, https://doi.org/10.1089/ct.2023;35.512-514
- Wijewardene A, Bastard K, Wang B, Gild ML, Luxford C, Gill A, Robinson B, Bullock M, Clifton-Bligh R. Response to Szymczak et al. re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion". Thyroid. 2023 Nov 16.
- White E, Abbot B, Schembri G, Glover A, Clifton-Bligh R, Gild M “Development of a novel clinical support tool for active surveillance of low risk papillary thyroid cancer” Frontiers Endocrinology 2023 Sep 11;14:1160249
- Worrall BJ, Papachristos A, Aniss A, Glover A, Sidhu SB, Clifton-Bligh RJ, Learoyd D, Tsang VHM, Gild M, Robinson BG, Sywak MS. “Lobectomy and completion thyroidectomy rates increase after the 2015 ATA Differentiated Thyroid Cancer Guidelines update. Endocr Oncol. 2023 Mar 13;3(1):e220095
- Chou A…Gild M….Glover A, Gill A “A detailed histological and molecular assessment of the diffuse sclerosing variant of papillary thyroid carcinoma” Modern Pathology 2023 Sep 15;36(12):100329.
- Gild ML, Clifton-Bligh R, Wirth L, Robinson B “Medullary Thyroid Cancer Updates and Challenges” Endocrine Reviews May 2023
- Kumar, S, Gild, M, Tsang V “ Neoadjuvant BRAF-Directed Therapy Is Associated with Favorable Surgical and Survival Outcomes in Patients with BRAF-Mutated Anaplastic Thyroid Cancer” Clinical Thyroidology, May 2023 p208-211.
- Kesby, N, Mechera R, Fuchs, T, …..Gild M....Sywak, M, Glover, “Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma”, JCEM 2023 Dec 21;109(1):e437
- Papachristos,A…Gild M…Sywak, M “Lobectomy and Completion Thyroidectomy Rates Increase …Thyroid Cancer Guidelines Update” Endocrine Oncology 2023 Mar 13;3(1):e220095.
- Crayton H… Gild M, Glover A.”Diffuse sclerosing variant papillary thyroid carcinoma has worse survival than classic papillary thyroid carcinoma: a meta-analysis”. Endocr Relat Cancer. 2023 Mar 1:ERC-22-0348
- Gild ML, Bullock M, Tsang V, Clifton-Bligh RJ, Robinson BG, Wirth LJ. “Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics”. Thyroid. 2023 Apr 21.